Concepts (75)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colitis, Ulcerative | 4 | 2024 | 74 | 1.740 |
Why?
|
| Inflammatory Bowel Diseases | 3 | 2023 | 102 | 1.050 |
Why?
|
| Gastrointestinal Agents | 2 | 2024 | 26 | 0.990 |
Why?
|
| Infliximab | 2 | 2024 | 50 | 0.980 |
Why?
|
| Crohn Disease | 3 | 2023 | 110 | 0.870 |
Why?
|
| Cost Savings | 1 | 2024 | 54 | 0.850 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2024 | 29 | 0.830 |
Why?
|
| Pancreatitis | 1 | 2023 | 97 | 0.770 |
Why?
|
| Biological Products | 1 | 2023 | 96 | 0.720 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2015 | 11 | 0.480 |
Why?
|
| Rifamycins | 1 | 2015 | 1 | 0.480 |
Why?
|
| Aminoglycosides | 1 | 2015 | 11 | 0.470 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2015 | 20 | 0.470 |
Why?
|
| Tamoxifen | 1 | 2015 | 41 | 0.470 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2015 | 35 | 0.470 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 89 | 0.470 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2015 | 34 | 0.460 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2015 | 79 | 0.450 |
Why?
|
| Venous Thrombosis | 1 | 2015 | 115 | 0.440 |
Why?
|
| Anti-Infective Agents | 1 | 2015 | 150 | 0.410 |
Why?
|
| Intensive Care Units | 1 | 2015 | 406 | 0.370 |
Why?
|
| Acute Disease | 2 | 2024 | 672 | 0.370 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 1198 | 0.250 |
Why?
|
| Hypokalemic Periodic Paralysis | 1 | 2005 | 2 | 0.230 |
Why?
|
| Hyperthyroidism | 1 | 2005 | 19 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 2 | 2021 | 724 | 0.220 |
Why?
|
| Drug Costs | 1 | 2024 | 56 | 0.210 |
Why?
|
| Inpatients | 1 | 2024 | 305 | 0.180 |
Why?
|
| Gastroenterology | 1 | 2021 | 41 | 0.170 |
Why?
|
| Infection Control | 1 | 2021 | 106 | 0.160 |
Why?
|
| Disease Progression | 1 | 2023 | 1173 | 0.150 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2022 | 236 | 0.140 |
Why?
|
| Humans | 10 | 2024 | 63512 | 0.130 |
Why?
|
| Hospitalization | 1 | 2024 | 1364 | 0.130 |
Why?
|
| Portal Vein | 1 | 2015 | 38 | 0.120 |
Why?
|
| Syncope | 1 | 2015 | 42 | 0.120 |
Why?
|
| Endoscopy, Digestive System | 1 | 2015 | 33 | 0.120 |
Why?
|
| Drug Monitoring | 1 | 2016 | 121 | 0.120 |
Why?
|
| Treatment Outcome | 2 | 2015 | 5699 | 0.110 |
Why?
|
| Blood Transfusion | 1 | 2015 | 162 | 0.110 |
Why?
|
| Middle Aged | 3 | 2024 | 17641 | 0.110 |
Why?
|
| Integrin alpha4 | 1 | 2013 | 4 | 0.110 |
Why?
|
| Retrospective Studies | 2 | 2024 | 6670 | 0.100 |
Why?
|
| Recurrence | 1 | 2015 | 644 | 0.100 |
Why?
|
| Adult | 4 | 2024 | 16837 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 238 | 0.090 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 378 | 0.090 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 774 | 0.090 |
Why?
|
| Female | 4 | 2024 | 32912 | 0.080 |
Why?
|
| Colonoscopes | 1 | 2010 | 3 | 0.080 |
Why?
|
| Male | 5 | 2024 | 29927 | 0.080 |
Why?
|
| Adenoma | 1 | 2010 | 70 | 0.080 |
Why?
|
| Colonoscopy | 1 | 2010 | 100 | 0.080 |
Why?
|
| Colonic Neoplasms | 1 | 2010 | 222 | 0.070 |
Why?
|
| Remission Induction | 2 | 2016 | 148 | 0.060 |
Why?
|
| Prebiotics | 1 | 2022 | 16 | 0.050 |
Why?
|
| Dysbiosis | 1 | 2022 | 65 | 0.040 |
Why?
|
| Disease Management | 1 | 2021 | 232 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2021 | 379 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 1008 | 0.040 |
Why?
|
| Diet | 1 | 2022 | 527 | 0.040 |
Why?
|
| Natalizumab | 1 | 2013 | 11 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 864 | 0.030 |
Why?
|
| Safety | 1 | 2013 | 145 | 0.020 |
Why?
|
| Boston | 1 | 2013 | 253 | 0.020 |
Why?
|
| Disposable Equipment | 1 | 2010 | 5 | 0.020 |
Why?
|
| Colonic Polyps | 1 | 2010 | 25 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 1749 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 358 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 1230 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 2462 | 0.020 |
Why?
|
| Young Adult | 1 | 2016 | 4700 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2010 | 3301 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 5471 | 0.010 |
Why?
|
| Aged | 1 | 2010 | 14469 | 0.010 |
Why?
|